| 陈亚楠1 张菊2 刘文超1.EGFR 突变种类与临床疗效关联[J].,2011,11(5):943-945 |
| EGFR 突变种类与临床疗效关联 |
| Relationship between Mutations of the Epidermal Growth Factor ReceptorGene and Clinical Evaluation |
| |
| DOI： |
| 中文关键词: 表皮生长因子受体(EGFR) 突变 非小细胞肺癌（NSCLC） 分子靶向治疗 |
| 英文关键词: EGFR Mutation NSCLC Tumor-Targeted Therapy |
| 基金项目:国家自然科学基金（30973437） |
|
| 摘要点击次数: 834 |
| 全文下载次数: 1922 |
| 中文摘要: |
| 癌组织中表皮生长因子受体(epidermal growth factor receptor,EGFR) 基因突变是应用靶向药物EGFR 酪氨酸激酶抑制剂
(tyrosine kinase inhibitor,TKI)治疗的一个重要相关因素及预测指标。对其突变的检测可以指导TKI 类药物（TKIs）的最佳应用。该
种突变常出现在非小细胞肺癌（NSCLC）中，尤其是在亚洲女性、肺腺癌、非吸烟者中，与非小细胞肺癌患者对TKIs 治疗的敏感性
密切相关。本文旨在探讨利用EGFR 基因的已知突变热点的相关知识选择适合不同分子遗传学背景的群体或/ 和个体的“个体
化”治疗方案，最终达到延长肺癌患者生存时间和提高生活质量的双重目的。 |
| 英文摘要: |
| Mutations in the epidermal growth factor receptor (EGFR) gene have been reported to be present in cancer organizes
and related to the responsiveness of tumors to EGFR tyrosine kinase inhibitors, which suggest its usefulness as a biomarker. Morever,
EGFR gene mutation was frequently tested in NSCLC, especially in Asians, females, nonsmokers, and adenocarcinomas. EGFR gene
mutation was related to gefitinib therapy sensibility. This article was to discuss "individuation". Extension patient's life and enhancement
quality of life could be achieved finally. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
